

**UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
June 30, 2017**

**ORDER GRANTING CONFIDENTIAL TREATMENT
UNDER THE SECURITIES ACT OF 1933**

Immune Design Corp.

File No. 333-196979 - CF#35121

Immune Design Corp. submitted an application under Rule 406 requesting an extension of a previous grant of confidential treatment for information it excluded from the Exhibits to a Form S-1 registration statement filed on June 23, 2014, as amended.

Based on representations by Immune Design Corp. that this information qualifies as confidential commercial or financial information under the Freedom of Information Act, 5 U.S.C. 552(b)(4), the Division of Corporation Finance has determined not to publicly disclose it. Accordingly, excluded information from the following exhibit(s) will not be released to the public for the time period(s) specified:

Exhibit 10.15	through May 10, 2020
Exhibit 10.16	through May 10, 2020
Exhibit 10.17	through May 10, 2020
Exhibit 10.18	through May 10, 2020
Exhibit 10.19	through May 10, 2020
Exhibit 10.20	through May 10, 2020

For the Commission, by the Division of Corporation Finance, pursuant to delegated authority:

Brent J. Fields
Secretary